摘要:
The invention concerns a pharmaceutical composition designed to adhere to a mucous membrane in particular for preventing or treating radiotherapy-related and chemotherapy-related mucositis, induced by radiotherapy or combined radiochemotherapy, comprising an efficient amount of an antiradical compound mixed with a vehicle which is liquid at room temperature and gels at the mucous membrane temperature and capable of adhering to the mucous membrane by its gelled state.
摘要:
The invention concerns compounds of formula (I) wherein: R1, R2, R3, R4 and R5 are as defined in Claim 1. Said compounds are useful in therapy as antithrombotic agents.
摘要:
The invention concerns compounds of formula (I) wherein: R1, R2, R3, Z1, Z2 are as defined in Claim 1. Said compounds inhibit the fixing of fibrinogen on Gp IIb/IIIa platelet receptors and are useful in therapy as antithrombotic agents.
摘要:
The invention concerns a composition having an activity on the proliferation of clonogenic cells in tumours and comprising a therapeutically efficient amount of a flavonoid, in particular a compound selected among the compounds of formula (I) wherein: R1, R2, R3 and R4, R5 and R6 are as defined in Claim 2. Said composition is designed for use in the treatment of tumours with cytotoxic agents.
摘要:
The invention concerns compounds of formula (I) in which: n = 1 or 2, and R1 is a group selected among the 2,4,6-trimethoxyphenyl, 2-thienyl and 2-pyrrolyl groups, and their additive salts with pharmaceutically acceptable acids.
摘要:
La présente invention concerne des composés de formule :
dans laquelle A est choisi parmi les groupes pyrrolidino, pipéridino, morpholino, 1-imidazolyle, hexaméthylène imino, 1-pipérazinyle, ces groupes étant non substitués ou pouvant comporter 1 ou 2 substituants choisis parmi les groupes alkyle en C₁-C₃ et hydroxyalkyle en C₁-C₃, et les sels d'addition de ces composés avec des acides pharmaceutiquement acceptables. Ces composés sont utilisables en thérapeutique comme vasodilatateurs périphériques.
摘要:
La présente invention concerne la 1-(4-aminophényl)-2-hexaméthylèneiminopropanone et ses sels d'addition pharmaceutiquement acceptables. Ces produits sont utiles en thérapeutique en raison de leurs effets antidépresseurs sur le SNC et de leurs propriétés immunologiques.